Skip to main content
. 2017 Nov 21;596(1):31–46. doi: 10.1113/JP275050

Figure 4. Effects of omecamtiv mecarbil and blebbistatin on the ATPase activity of cardiomyofibrils.

Figure 4

A–C, steady‐state ATPase rates for control, OM treated and BS treated CMFs at pCa 9 (A), pCa 6 (B) and pCa 4.3 (C). Values indicate means ± SEM (n = 4–8). D, dose–response curve for the effect of omecamtiv mecarbil on steady‐state cardiomyofibriliar ATPase activity at pCa 4.3. Statistical significance of differences between groups were assessed by a one‐way ANOVA with Turkey's post hoc test: ** P < 0.01; *** P < 0.001.